循环肿瘤DNA揭示前列腺导管内癌患者的遗传特征
该研究对161例伴导管内癌(IDC-P)和84例不伴IDC-P的前列腺腺癌患者进行血浆游离DNA靶向测序,比较两组基因组改变及其与生存的关系。结果显示IDC-P患者胚系DNA修复改变和NCOR2突变富集,且TP53突变与更短的去势抵抗生存相关,BRCA2改变与阿比特龙治疗快速PSA进展相关。
要点
- IDC-P患者胚系DNA修复改变频率高于无IDC-P者(11.8% vs 2.4%)。
- IDC-P患者NCOR2突变富集(21.1% vs 6.0%),AR通路改变独特。
- TP53突变与IDC-P患者更短去势抵抗生存相关。
核心结论
- IDC-P患者具有独特的基因组改变谱,包括胚系DNA修复缺陷和NCOR2突变富集,解释了其侵袭性表型。
研究设计与样本
- 对161例伴IDC-P和84例不伴IDC-P的前列腺腺癌患者进行血浆游离DNA靶向测序,比较基因组改变并探索与生存的关联。
主要发现
- IDC-P患者与无IDC-P患者DNA修复通路基因组改变比例分别为29.8%(48/161)和21.4%(18/84),P=0.210。
- 胚系DNA修复致病性改变在IDC-P携带者中更常见(11.8% [19/161] vs 2.4% [2/84],P=0.024)。
- 胚系BRCA2和体细胞CDK12缺陷仅在IDC-P携带者中特异识别(BRCA2:8.7% [14/161] vs 0%;CDK12:6.8% [11/161] vs 1.2% [1/84])。
- IDC-P患者NCOR2突变富集(21.1% [34/161] vs 6.0% [5/84],P=0.004)。
- IDC-P比例≥10%者AR改变高于<10%者(18.1% [15/83] vs 6.4% [5/78],P=0.045)。
关键数值与推荐
- IDC-P携带者中TP53突变与更短的去势抵抗生存相关(中位10.9 vs 28.9个月,P=0.026)。
- 接受阿比特龙治疗的IDC-P携带者中BRCA2改变与快速PSA进展相关(中位9.1 vs 11.9个月,P=0.036)。
临床怎么用
- 对IDC-P患者可考虑胚系DNA修复基因检测,尤其关注BRCA2。
- IDC-P患者治疗决策时可参考TP53和BRCA2状态评估预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the genetic alterations of patients with prostate cancer (PCa) with and without intraductal carcinoma of the prostate (IDC-P). PATIENTS AND METHODS: We performed targeted sequencing of plasma cell-free DNA on 161 patients with prostate adenocarcinoma (PAC) with IDC-P and 84 without IDC-P. Genomic alterations were compared between these two groups. The association between genetic alterations and patients' survival outcomes was also explored. RESULTS: We identified that 29.8% (48/161) and 21.4% (18/84) of patients with and without IDC-P harboured genomic alterations in DNA repair pathways, respectively (P = 0.210). Pathogenic germline DNA repair alterations were frequently detected in IDC-P carriers compared to IDC-P non-carriers (11.8% [19/161] vs 2.4% [two of 84], P = 0.024). Germline BReast CAncer type 2 susceptibility protein (BRCA2) and somatic cyclin-dependent kinase 12 (CDK12) defects were specifically identified in IDC-P carriers relative to PAC (BRCA2: 8.7% [14/161] vs 0% and CDK12: 6.8% [11/161] vs 1.2% [one of 84]). Patients with IDC-P had a distinct androgen receptor (AR) pathway alteration, characterised by an enrichment of nuclear receptor corepressor 2 (NCOR2) mutations compared with patients with pure PAC (21.1% [34/161] vs 6.0% [five of 84], P = 0.004). Increased AR alterations were detected in patients harbouring tumours with an IDC-P proportion of ≥10% vs those with an IDC-P proportion of <10% (6.4% [five of 78] vs 18.1% [15/83], P = 0.045). For IDC-P carriers, tumour protein p53 (TP53) mutation was associated with shorter castration-resistant-free survival (median 10.9 vs 28.9 months, P = 0.026), and BRCA2 alteration was related to rapid prostate-specific antigen progression for those receiving abiraterone treatment (median 9.1 vs 11.9 months, P = 0.036). CONCLUSION: Our findings provide genomic evidence explaining the aggressive phenotype of tumours with IDC-P, highlighting the potential therapeutic strategies for this patient population.
引用
- Zhao J, Sun G, Zhu S, et al. Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate. BJU Int. 2021. PMID: 34185954. doi:10.1111/bju.15530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。